According to the National Medical Insurance Administration on the 4th, since the beginning of 2023, in response to issues such as monopolistic control of sales and inflated costs of some drugs by a few enterprises, the National Medical Insurance Administration has interviewed a total of 23 enterprises throughout 2023, involving 30 varieties, with an average price reduction of over 40% for negotiated drugs. By continuously strengthening the normalization supervision of drug prices, the National Medical Insurance Administration comprehensively utilizes monitoring and early warning, inquiry and interview, credit evaluation, information disclosure and other means to effectively deal with a number of problems such as inflating raw material prices and forcing formulation prices to rise. The National Medical Insurance Administration stated that it supports pharmaceutical enterprises in providing high-quality, efficient, and affordable pharmaceutical products to the people through research and development innovation, consistency evaluation, and other means. It also supports pharmaceutical enterprises in compensating for costs and obtaining returns through fair and reasonable independent pricing. At the same time, it advocates for pharmaceutical enterprises to operate and price with integrity and legality, reflecting production costs, sales expenses, and corporate profits truthfully, We firmly oppose all forms of inflated costs and cashing out "sales with gold". (Le Xin She) (Reporter Peng Yunjia, Mu Tiecheng)